MiR-134, epigenetically silenced in gliomas, could mitigate the malignant phenotype by targeting KRAS.
Wang ZL, Zhang CB, Wang Z, Meng XQ, Liu XJ, Han B, Duan CB, Cai JQ, Hao ZF, Chen MH, Jiang T, Li YL, Jiang CL, Wang HJ.
Wang ZL, et al. Among authors: han b.
Carcinogenesis. 2018 Mar 8;39(3):389-396. doi: 10.1093/carcin/bgy022.
Carcinogenesis. 2018.
PMID: 29432532